Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$3.02+0.14 (+4.86%)
Close on Nov 18, 2026Market cap $243.33MP/E 13.1Yield –
Protalix BioTherapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Protalix BioTherapeutics's price to book ratio was 3.6× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 2.5× to 178.3×, with a median of 3.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.6× | +0.7 |
| 2025 | Dec 31, 2025 | 2.9× | −1.6 |
| 2024 | Dec 31, 2024 | 4.6× | +1.3 |
| 2023 | Dec 29, 2023 | 3.2× | −159.1 |
| 2022 | Jan 31, 2022 | 162.3× | +2.0 |
| 2021 | Dec 31, 2021 | 160.3× | +136.6 |
| 2016 | Jul 29, 2016 | 23.7× | −72.7 |
| 2013 | Jan 31, 2013 | 96.4× | −1.5 |
| 2012 | Dec 31, 2012 | 97.9× | – |
See a number that looks wrong?